Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) (Descending) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
16714-0859-01 16714-0859 Cyclophosphamide Cyclophosphamide 500.0 mg/25mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous, Oral Jan. 8, 2019 In Use
16714-0858-01 16714-0858 Cyclophosphamide Cyclophosphamide 2.0 g/100mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous, Oral Jan. 8, 2019 In Use
16714-0857-01 16714-0857 Cyclophosphamide Cyclophosphamide 1.0 g/50mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous, Oral Jan. 8, 2019 In Use
16714-0856-01 16714-0856 Doxorubicin Hydrochloride Doxorubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Aug. 29, 2017 In Use
16714-0834-01 16714-0834 Palonosetron Palonosetron 0.05 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous May 29, 2018 In Use
16714-0816-02 16714-0816 Bicalutamide Bicalutamide 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral June 1, 2018 In Use
16714-0816-01 16714-0816 Bicalutamide Bicalutamide 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral June 1, 2018 In Use
16714-0815-01 16714-0815 Zoledronic Acid Zoledronic Acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous May 30, 2018 In Use
16714-0777-01 16714-0777 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous May 4, 2018 June 10, 2020 In Use
16714-0742-01 16714-0742 Doxorubicin Hydrochloride Doxorubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Aug. 29, 2017 In Use
16714-0728-01 16714-0728 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous June 15, 2017 In Use
16714-0727-01 16714-0727 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous June 15, 2017 In Use
16714-0726-01 16714-0726 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous June 15, 2017 April 30, 2020 In Use
16714-0725-01 16714-0725 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous June 15, 2017 April 30, 2020 In Use
16714-0679-01 16714-0679 Sunitinib malate Sunitinib malate 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Feb. 18, 2022 In Use
16714-0678-01 16714-0678 Sunitinib malate Sunitinib malate 37.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Feb. 18, 2022 In Use
16714-0677-01 16714-0677 Sunitinib malate Sunitinib malate 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Feb. 18, 2022 In Use
16714-0676-01 16714-0676 Sunitinib malate Sunitinib malate 12.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Feb. 18, 2022 In Use
16714-0671-02 16714-0671 Ondansetron Hydrochloride Ondansetron 4.0 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Nov. 28, 2007 In Use
16714-0671-01 16714-0671 Ondansetron Hydrochloride Ondansetron 4.0 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Nov. 28, 2007 Oct. 31, 2016 In Use
16714-0578-01 16714-0578 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Nov. 18, 2022 In Use
16714-0572-01 16714-0572 Leuprolide acetate Leuprolide acetate Hormonal Therapy GnRH Agonist Aug. 1, 2022 In Use
16714-0571-03 16714-0571 Bicalutamide Bicalutamide 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Aug. 28, 2009 Sept. 30, 2019 In Use
16714-0571-02 16714-0571 Bicalutamide Bicalutamide 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Aug. 28, 2009 Sept. 30, 2019 In Use
16714-0571-01 16714-0571 Bicalutamide Bicalutamide 50.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Aug. 28, 2009 Sept. 30, 2019 In Use
16714-0522-10 16714-0522 Finasteride Finasteride Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Sept. 19, 2012 Aug. 31, 2014 No Longer Used
16714-0522-05 16714-0522 Finasteride Finasteride Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral March 4, 2011 Feb. 28, 2015 No Longer Used
16714-0522-04 16714-0522 Finasteride Finasteride Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral March 2, 2011 Feb. 28, 2015 No Longer Used
16714-0522-03 16714-0522 Finasteride Finasteride Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral March 2, 2011 Feb. 28, 2015 No Longer Used
16714-0522-02 16714-0522 Finasteride Finasteride Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral March 2, 2011 March 4, 2011 No Longer Used
16714-0522-01 16714-0522 Finasteride Finasteride Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral March 4, 2011 Feb. 28, 2015 No Longer Used
16714-0500-01 16714-0500 Docetaxel Docetaxel 80.0 mg/4mL Chemotherapy Antimitotic Agent Taxane Intravenous Jan. 1, 2016 Nov. 30, 2018 No Longer Used
16714-0473-01 16714-0473 Methylprednisolone Acetate Methylprednisolone Acetate 80.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intralesional, Intramuscular, Intrasynovial, Soft Tissue May 25, 2021 In Use
16714-0472-25 16714-0472 Methylprednisolone Acetate Methylprednisolone Acetate 80.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-articular, Intralesional, Intramuscular, Soft Tissue May 25, 2021 In Use
16714-0472-01 16714-0472 Methylprednisolone Acetate Methylprednisolone Acetate 80.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-articular, Intralesional, Intramuscular, Soft Tissue May 25, 2021 In Use
16714-0468-01 16714-0468 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Nov. 1, 2015 In Use
16714-0467-01 16714-0467 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Nov. 1, 2015 In Use
16714-0465-01 16714-0465 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Jan. 1, 2016 Nov. 30, 2018 No Longer Used
16714-0248-01 16714-0248 Fosaprepitant dimeglumine Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Jan. 28, 2023 In Use
16714-0221-32 16714-0221 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 29, 2008 Aug. 31, 2021 No Longer Used
16714-0221-30 16714-0221 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 29, 2008 Aug. 31, 2021 No Longer Used
16714-0221-12 16714-0221 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 29, 2008 Aug. 31, 2021 No Longer Used
16714-0221-10 16714-0221 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 29, 2008 Aug. 31, 2021 No Longer Used
16714-0221-01 16714-0221 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 29, 2008 Aug. 31, 2021 No Longer Used
16714-0201-30 16714-0201 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 27, 2021 In Use
16714-0201-10 16714-0201 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 27, 2021 In Use
16714-0200-30 16714-0200 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 27, 2021 In Use
16714-0160-01 16714-0160 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 6, 2021 In Use
16714-0159-01 16714-0159 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 6, 2021 In Use
16714-0150-01 16714-0150 Triamcinolone Acetonide Triamcinolone Acetonide 400.0 mg/10mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-articular, Intramuscular Nov. 19, 2019 In Use

Found 10,000 results in 12 millisecondsExport these results